抑制HDAC11会触发双模热生成通路,以规避脂肪细胞对catecholamine的抗性
Emma L Robinson1,2, Rushita A Bagchi1,2, Jennifer L Major1,2
1Department of Medicine, Division of Cardiology.
在脂肪细胞中抑制基因组脱乙酶11 (HDAC11) 会促进脱蛋白1 (UCP1) 进行热生成. 这种方法即使在β-上腺素受体 (β-AR) 信号被阻断时也起作用,提供了一种新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 代谢研究的研究.
- 脂肪细胞生物学 脂肪细胞生物学
背景情况:
- 刺激脂肪细胞β-上腺素受体 (β-ARs) 会增加解蛋白1 (UCP1) 进行热生成.
- 信号传输需要β-ARs与化甲基酶定蛋白12 (AKAP12) 相结合.
- 希斯脱乙酶11 (HDAC11) 通过去化AKAP12来抑制这种途径.
研究的目的:
- 为了研究是否抑制脂肪细胞中的HDAC11可以诱导UCP1的表达独立于β-ARs.
- 探索HDAC11抑制对改变脂肪组织表型的治疗潜力.
主要方法:
- 在小鼠中,脂肪细胞特异性HDAC11的删除.
- 用HDAC11抑制剂 (FT895) 对小鼠进行体内治疗和对人类脂肪组织 (AT) 进行体外治疗.
- 分析UCP1表达,AKAP12基化和蛋白质激酶A (PKA) 活性.
主要成果:
- 脂肪细胞特定的HDAC11删除强烈诱导AT中的UCP1,增加体温.
- FT895治疗模仿了这些效应,显示了双相,AKAP12依赖于基基化的UCP1诱导.
- 抑制HDAC11促进了UCP1的表达,即使在抵抗β-AR信号的脂肪细胞中也是如此.
结论:
- 通过多模式的作用,HDAC11充当细胞自主抑制热生成的抑制剂.
- 抑制HDAC11提供了一种潜在的治疗策略,可以独立于β-AR刺激来增强热生成.
- 这突出了调节脂肪组织功能和能量消耗的新途径.
更多相关视频
04:46Differentiation and Imaging of Brown Adipocytes from the Stromal Vascular Fraction of Interscapular Adipose Tissue from Newborn Mice
Published on: February 3, 2023
09:41Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
相关概念视频
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
GPCRs Regulate Adenylyl Cylase Activity
cAMP-dependent Protein Kinase Pathways
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
